This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population

Japanese Encephalitis Clinical Trial

Official title:

An Open-label, Uncontrolled Phase 4 Study to Assess the Safety and Immunogenicity of the Japanese Encephalitis (JE) Vaccine Ixiaro® (IC51) in an Elderly Population

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01158599
• Other study ID #: IC51-315
• Status: Completed
• Phase: Phase 4
• First received: July 7, 2010
• Last updated: March 22, 2012
• Start date: June 2010
• Est. completion date: October 2011

Study information

• Verified date: March 2012
• Source: Valneva Austria GmbH
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Paul-Ehrlich-InstitutAustria: Agency for Health and Food Safety
• Study type: Interventional

Clinical Trial Summary

This is an open-label, uncontrolled phase 4 study to assess the safety and immunogenicity of the Japanese encephalitis (JE) vaccine Ixiaro® (IC51) in an elderly population.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: October 2011
• Est. primary completion date: June 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Male or female subjects = 65 years of age at the time of 1st vaccination of good general health status including subjects with pharmacologically controlled conditions like hypercholesterolemia, hypertension, cardiovascular disease or non insulin-dependent diabetes mellitus

• Weight: = 45.5 kg and = 150 kg at Visit 0 (Screening Visit)

• White blood cells =2,500/mm3 and <11,000/mm3 at Visit 0

• Absolute neutrophil count within normal limits at Visit 0

• Platelets within normal limits at Visit 0

• Written informed consent obtained from the subject prior to any study related procedures

Exclusion Criteria:

• History of clinical manifestation of any flavivirus infection (Yellow Fever, Dengue Fever, JE, Tick Borne Encephalitis (TBE) and West Nile Fever/Neuroinvasive Disease)

• Vaccination against JE (including study participation in any previous or current IC51/IXIARO® clinical study), Yellow fever, Dengue Fever or West Nile Fever at any time prior or during the study

• Vaccination against TBE within 30 days prior to first IXIARO® vaccination at Visit 1 (Day 0) and until Visit 3 (Day 70)

• Use of any other investigational or non-registered medicinal product within 30 days prior to IXIARO® vaccination at Visit 1 (Day 0) and throughout the entire study period

• Immunodeficiency including status post-organ-transplantation or immuno-suppressive therapy, and a family history of congenital or hereditary immunodeficiency

• Infection with the human immunodeficiency virus (HIV, a negative test result within 30 days before screening is acceptable), Hepatitis B virus (HBV, Hepatitis B surface antigen [HBsAg]) or Hepatitis C virus (HCV)

• Administration of chronic (defined as longer than 14 days) immunosuppressants or other immune-modifying drugs within 30 days prior to IXIARO® vaccination at Visit 1 (Day 0) and during the study until Visit 3 (Day 70). (For corticosteroids this means prednisone or equivalent >= 0.05 mg/kg/day; topical and inhaled steroids are allowed).

• Periodic steroid injections, e.g., intra-articular, are not allowed within 30 days prior to first IXIARO® vaccination at Visit 1 (Day 0) and until Visit 3 (Day 70)

• History of autoimmune disease, including Type I Diabetes mellitus. Subjects with vitiligo or thyroid disease taking thyroid hormone replacement are not excluded.

• Acute febrile infections or exacerbation of chronic infection on the day of IXIARO® vaccination (Day 0 and Day 28)

• Skin cancer in the past six months. If treatment for skin cancer was successfully completed more than six months ago and the malignancy is considered to be cured, the subject may be enrolled. Subjects with history of skin cancer must not be vaccinated at the previous site of the malignancy.

• Any other malignancy in the past 5 years. If treatment for cancer was successfully completed more than 5 years ago and the malignancy is considered to be cured, the subject may be enrolled.

• Clinically significant hematological, renal, hepatic, pulmonary, central nervous, cardiovascular or gastrointestinal disorders, which are not adequately controlled by medical treatment within the last 12 weeks before IXIARO® vaccination at Visit 1 (Day 0) as judged by the site's Principal Investigator

• Clinically significant mental disorder not adequately controlled by medical treatment

• History of Guillain-Barré-Syndrome (GBS).

• History of severe hypersensitivity reactions, in particular to a component of the IXIARO® vaccine (e.g. protamine sulfate), anaphylaxis or severe cases of atopy requiring emergency treatment or hospital admission

• History of urticaria after hymenoptera envenomation, drugs, physical or other provocations, or of idiopathic cause

• Drug addiction within 6 months prior to Visit 0 and throughout the entire study period (including alcohol dependence, i.e. more than approximately 60 g alcohol per day, or conditions which might interfere with the study conduct)

• Inability or unwillingness to avoid more than the usual intake of alcohol (> 60 g alcohol/day) during the 48 hours after each vaccination

• Any condition which might interfere with study objectives or would limit the subject's ability to complete the study in the opinion of the investigator

• Persons who are committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities) will not participate in the study

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Encephalitis
• Encephalitis, Japanese
• Japanese Encephalitis

Intervention

Biological:
• IXIARO®
IXIARO®, 0.5 ml (6 µg), intramuscular (i.m.) injection, two vaccinations, Days 0 and 28

Locations

Country	Name	City	State
Austria	Institut für Spezifische Prophylaxe und Tropenmedizin	Vienna
Austria	Medical University of Vienna - Klinische Pharmakologie	Vienna
Germany	Berliner Centrum Reise- und Tropenmedizin	Berlin
Germany	Universitätsklinikum Hamburg-Eppendorf	Hamburg
Germany	Universitätsklinikum Rostock	Rostock

Sponsors (1)

Lead Sponsor	Collaborator
Valneva Austria GmbH

Countries where clinical trial is conducted

Austria,  Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of subjects with serious adverse events (SAEs) and medically attended adverse events (AEs) during the vaccination period and until Day 70 after the first vaccination		until day 70	Yes
Secondary	Rate of subjects with SAEs and medically attended AEs during the vaccination period and up to 6 months after the second vaccination		up to 6 months	Yes
Secondary	Rate of subjects with unsolicited AEs up to Day 70 after the first vaccination		up to Day 70	Yes
Secondary	Rate of subjects with unsolicited AEs up to six months after the second vaccination		up to 6 months	Yes
Secondary	Rate of subjects with abnormal safety laboratory parameters (hematology, clinical chemistry, urinalysis) up to Day 70 after the first vaccination		up to Day 70	Yes
Secondary	Rate of subjects with solicited local and solicited systemic AEs assessed with a subject diary for 7 consecutive days after each vaccination		7 consecutive days after each vaccination	Yes
Secondary	GMTs and SCRs for JEV neutralizing antibodies determined by PRNT at Day 70		Day 70	No